Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.
Munenori OyamaKensuke OkadaMasayuki MasudaYuko ShimizuKazumasa YokoyamaAkiyuki UzawaNaoki KawaguchiRyotaro IkeguchiYasunobu HoshinoTaku HatanoYukiko OzawaJin NakaharaHitoshi AizawaKazuo KitagawaNobutaka HattoriSatoshi KuwabaraHiroyuki MuraiShigeaki SuzukiPublished in: Therapeutic advances in neurological disorders (2020)
We demonstrate that eculizumab provided remarkable benefits for refractory gMG in practical real-world experience as well as in the REGAIN study. Patients with refractory gMG with myasthenia crisis and thymoma-associated MG are suitable for eculizumab administration.